Finanzen von Transmedics Group Inc (TMDX)TMDXTransmedics Group Inc

TransMedics Group, Inc. (TMDX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is OCS Liver net revenue, accounting for 78.5% of total sales, equivalent to $148.23M. Other significant revenue streams include OCS Heart net revenue and OCS Lung net revenue. Understanding this composition is critical for investors evaluating how TMDX navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, TransMedics Group, Inc. maintains a gross margin of 59.59%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.50%, while the net margin is 7.73%. These profitability ratios, combined with a Return on Equity (ROE) of 36.28%, provide a clear picture of how effectively TMDX converts its operational activities into shareholder value.

In the context of the broader market, TMDX competes directly with industry leaders such as NEOG and CELC. With a market capitalization of $2.50B, it holds a significant position in the sector. When comparing efficiency, TMDX's gross margin of 59.59% stands against NEOG's 37.03% and CELC's N/A. Such benchmarking helps identify whether TransMedics Group, Inc. is trading at a premium or discount relative to its financial performance.

Transmedics reported a revenue increase of nearly 21% year-over-year to $189.9 million in Q2 2026, but adjusted EPS fell 52% from the previous year, indicating pressure on profitability. Gross margin has been relatively stable, around 59.59% in Q2 2026, but net margin has fluctuated, showing a decline to 7.73% in Q2 2026 from a high of 65.55% in Q4 2025.